NBD AI Bulletin - Guangzhou Wondfo Biotech Co., Ltd. ("the Company", SZ 300482, closing price: 89.25 yuan) released earnings forecast on January 18, expecting net profit attributable to shareholders of the listed company to be about 581 million yuan~659 million yuan in 2020, up 50%~70% from a year ago.

The change in performance is due to that after the outbreak of the COVID-19, sales of the Company's antibody reagent test kit for novel coronavirus and antigen reagent test kit for novel coronavirus rose rapidly, pushing up the Company's business growth in 2020. The regular business lines were affected by the pandemic at different degrees. The immunofluorescence platform business was largely affected in the first half of 2020 and gradually recovered in the second half with hospitals returning to normal. The immune colloidal gold platform business showed slow growth due to the slowdown of morbidity of respiratory diseases. In overseas markets, the virus check business of the U.S. subsidiary and immunofluorescence platform business of the international business division delivered great performance, strongly driving the overall overseas business.

The 2019 annual report shows that Guangzhou Wondfo Biotech Co., Ltd. mainly engages in diagnostic products, trade, accounting for 77.64%, 22.04% of revenue, respectively.

Guangzhou Wondfo Biotech Co., Ltd.'s chairman is Wang Jihua, 59 years old, Chinese national, no permanent residence abroad, graduated from the National Laboratory of Enzyme Engineering, Jilin University, master's degree. Guangzhou Wondfo Biotech Co., Ltd.'s general manager is Li Wenmei, male, 59 years old, Chinese national, no permanent residence abroad, master's degree.

Tips on "Stock Trends":

1. The number of shares held by northbound investors decreased by 760,900 in the past 30 days, representing 0.32% of the Company's circulating shares.

2. There was no institutional research on the Company in the past 30 days. 3. According to predictions of securities firms, the average net profit for 2020 of the Company is 693 million yuan. The Company's net profit was 387 million yuan a year ago.

(By Lan Suying)

Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.